The TKI Era in Chronic Leukemias
Tyrosine kinases are proteins involved in physiological cell functions including proliferation, differentiation, and survival. However, the dysregulation of tyrosine kinase pathways occurs in malignancy, including hematological leukemias such as chronic myeloid leukemia (CML) and chronic lymphocytic...
Saved in:
Main Authors: | Danilo De Novellis (Author), Fabiana Cacace (Author), Valeria Caprioli (Author), William G. Wierda (Author), Kris M. Mahadeo (Author), Francesco Paolo Tambaro (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
by: Tambaro FP, et al.
Published: (2021) -
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells
by: Paola Pacelli, et al.
Published: (2023) -
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era
by: María Del Mar Sánchez Suárez, et al.
Published: (2023) -
The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011) -
TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
by: Jin Lei, et al.
Published: (2022)